Three Drug Firsts, Record Ebola Toll, and Dengue in Marseille

The last week of August delivers three first-in-class drug approvals from the US Food and Drug Administration, a worsening Ebola-family outbreak that has now become the second-largest in recorded history, and a confirmed case of locally contracted dengue fever in Marseille — a warning for the entire northern Mediterranean, including Cyprus.

Tuesday, 26 August: A First Targeted Drug for Pancreatic Cancer

The FDA approved daraxonrasib (brand name RASONQUE, Revolution Medicines) for adults with metastatic pancreatic adenocarcinoma who have received at least one prior line of therapy, or who cannot tolerate multiagent chemotherapy. It is the first drug in a new class of pan-RAS inhibitors to reach patients with this cancer — one of the deadliest solid tumours, with a five-year survival rate below 3% for metastatic disease.

The pivotal RASolute 302 trial was a randomised, open-label, multicentre study in 500 previously treated adults. Daraxonrasib extended median overall survival to 13.2 months, compared with 6.7 months on standard-of-care chemotherapy — a near-doubling that represents the largest improvement seen in a randomised pancreatic cancer trial in more than a decade.

RAS-family mutations (principally KRAS) drive roughly 90% of pancreatic cancers and had long been considered undruggable because the protein's smooth surface offered no obvious binding site for small molecules. Daraxonrasib binds across the RAS protein family rather than targeting a single mutation, blocking the downstream signals that drive tumour cell proliferation. The approval does not require prior genetic testing; any eligible patient with metastatic disease qualifies after first-line treatment.

Wednesday, 27 August: First Oral Treatment for Dermatomyositis

The FDA approved lisraya (brepocitinib), developed by Priovant Therapeutics, for adults with dermatomyositis — a rare autoimmune disease in which the immune system attacks both skeletal muscle and skin, causing progressive weakness and a characteristic rash. It is the first oral drug specifically indicated for this condition; patients have historically relied on off-label immunosuppressants or long-term corticosteroids that carry serious long-term risks, including bone loss and diabetes.

Brepocitinib is a selective inhibitor of two enzymes — TYK2 and JAK1 — that amplify the inflammatory cascade in dermatomyositis. In a Phase 3 trial of 241 adults, patients on the approved 30 mg daily dose showed significantly greater reduction in overall disease activity than those receiving placebo. Participants were also more likely to successfully taper off corticosteroids, reducing cumulative steroid exposure.

Dermatomyositis affects an estimated 9 to 32 per 100,000 people worldwide; it disproportionately affects women and, in severe forms, can cause interstitial lung disease and cardiac involvement. An EMA regulatory submission is expected to follow; a European decision typically comes 12–18 months after US approval.

Thursday, 28 August: A Hepcidin Mimetic Opens a New Path in Polycythemia Vera

The FDA approved rusfertide (MIMRYLO, Takeda) for adults with polycythemia vera (PV), a chronic myeloproliferative neoplasm in which the bone marrow overproduces red blood cells, raising the risk of clots, stroke, and transformation to acute leukaemia. It is the first approved treatment that works by mimicking hepcidin — the hormone the liver uses to regulate iron absorption and, downstream, red-cell production.

Current PV management relies on therapeutic phlebotomy (regular blood removal) and broadly immunosuppressive agents such as hydroxyurea. Rusfertide acts more selectively: by limiting the iron available for haemoglobin synthesis, it reduces haematocrit without suppressing the entire bone marrow. In the Phase 3 VERIFY trial, 76.9% of patients on rusfertide achieved a defined clinical response during weeks 20 to 32, compared with 38.5% on placebo. Patients also reported improved fatigue scores and a lower frequency of phlebotomy procedures. Rusfertide is given as a weekly subcutaneous injection.

Update: Bundibugyo Ebola in DRC Crosses a Grim Record

The Bundibugyo virus disease outbreak in the Democratic Republic of the Congo has become the second-largest Ebola-family outbreak ever recorded. As of 26 August, the WHO confirmed 5,794 cases and 2,786 deaths across six provinces — Bas-Uélé, Haut-Uélé, Ituri, North Kivu, South Kivu, and Tshopo — with 60 health zones now affected. The pace of spread continues to exceed that of all previous outbreaks in this virus species.

Bundibugyo virus is one of six known species in the Orthoebolavirus genus. Neither of the two currently approved Ebola vaccines — ERVEBO (Merck) and the Janssen two-dose regimen — was developed against Bundibugyo; both target the Zaire species. On 27 August, the DRC Ministry of Health launched an ERVEBO vaccination campaign for frontline and healthcare workers in Kisangani — a pragmatic decision in the absence of a species-specific tool, but one taken with awareness that cross-reactive immunity against Bundibugyo has not been established in clinical trials.

The first-ever Bundibugyo-specific candidate vaccine entered Phase 1 human trials in July 2026, with sites in the United Kingdom and Canada. Full safety and immunogenicity results are not expected before mid-2027. On a more hopeful note, WHO declared Uganda's outbreak over on 26 August, after 42 consecutive days without a new confirmed case. The CDC continues to advise against non-essential travel to the six affected DRC provinces.

Late August: Dengue Reaches Marseille — a Warning for the Mediterranean

French public health authorities confirmed the first case of locally contracted dengue fever in Marseille in late August 2026, triggering emergency mosquito-control operations across the city. The case involved a person who had not travelled outside France; the likely vector was Aedes albopictus — the Asian tiger mosquito — which has been established in southern France since the mid-2000s and has now spread into urban Marseille.

The detection matters for the entire northern Mediterranean. By 31 July 2026, the WHO had recorded more than 1.5 million dengue cases globally this year, with local transmission occurring in several southern European countries for the first time. Aedes albopictus is present in coastal Cyprus, where it has been under active surveillance by the Ministry of Health. Higher summer temperatures and an extended flight season — both consistent with eastern Mediterranean climate trends — lengthen the window during which local dengue transmission is possible.

Dengue causes febrile illness with severe muscle and joint pain; a small proportion of infections progress to severe dengue, with plasma leakage and organ involvement requiring hospital care. There is no licensed antiviral; treatment is supportive. Residents and visitors in Cyprus, Greece, and other eastern Mediterranean countries should use insect repellent, wear protective clothing at dawn and dusk, and eliminate standing water near homes.

Late August: Lecanemab Gets a Home-Injection Form as Alzheimer's Evidence Grows

Lecanemab (Leqembi, Eisai/Biogen), the anti-amyloid antibody approved for early Alzheimer's disease, received FDA clearance on 14 July 2026 for a subcutaneous self-injection formulation, and the manufacturer announced a US market launch in late August — ahead of autumn clinical cycles. The original formulation required bi-weekly intravenous infusions at an infusion centre; the new subcutaneous form is administered weekly by the patient at home, substantially reducing the logistical burden for early-stage patients and their caregivers.

The drug carries a boxed warning for amyloid-related imaging abnormalities (ARIA) — brain swelling or micro-bleeds that occur in roughly 35% of treated patients, most of whom are asymptomatic. Regular MRI monitoring remains required regardless of the administration route. The EMA approved lecanemab for early Alzheimer's in early 2026; availability in Cyprus and Greece is subject to national reimbursement decisions.

Separately, results from the POINTER trial — presented at the Alzheimer's Association International Conference (AAIC) this year — found that a structured two-year multidomain programme combining aerobic exercise, dietary counselling, cognitive training, and cardiovascular risk management produced modestly but statistically significantly greater improvement on a global cognitive composite than a self-guided wellness programme in older adults at elevated dementia risk. The results add to accumulating evidence that lifestyle interventions, begun before symptoms appear, can meaningfully slow cognitive decline — an approach accessible to anyone, regardless of drug availability.

---

This article is journalistic reporting and does not constitute medical advice. Readers should consult a qualified clinician before making any change to their treatment, medication, or health management plan.